| ecnoglutide SC (XW003) / Sciwind Biosci |
NCT05680129: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM |
|
|
| Active, not recruiting | 3 | 623 | RoW | Ecnoglutide high dosage, XW003, Ecnoglutide low dosage, Dulaglutide, Metformin | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05680155: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients |
|
|
| Active, not recruiting | 3 | 211 | RoW | Ecnoglutide, XW003, Placebo | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05813795: A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity |
|
|
| Active, not recruiting | 3 | 664 | RoW | Ecnoglutide Low Dosage, XW003, Ecnoglutide Medium Dosage, Ecnoglutide High Dosage, Placebo | Hangzhou Sciwind Biosciences Co., Ltd. | Weight Management | 06/24 | 01/25 | | |
NCT05111912: Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity |
|
|
| Completed | 2 | 206 | RoW | XW003, GLP-1 analogue, Saxenda | Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd. | Obesity | 11/22 | 12/22 | | |
ACTRN12620000344998: A Randomized, Double-blind, Placebo- controlled, Single Ascending Dose (SAD) Study of XW003 Injection in Healthy Adult Participants |
|
|
| Not yet recruiting | 1 | 50 | | | Sciwind Biosciences APAC CO Pty. Ltd., Sciwind Biosciences APAC CO Pty. Ltd. | Type 2 Diabetes Mellitus, Nonalcoholic Steatohepatitis | | | | |
NCT06335134: A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin |
|
|
| Recruiting | 1 | 56 | RoW | XW003 injection, ecnoglutide, Metformin, Warfarin, Rosuvastatin, Digoxin | Hangzhou Sciwind Biosciences Co., Ltd. | Healthy Volunteers | 01/24 | 03/24 | | |
ChiCTR2300075163: Pharmacokinetic Study of XW003 Injection in Subjects with Normal Renal Function and Renal Insufficiency |
|
|
| Recruiting | 1 | 30 | | This cohort evaluated the pharmacokinetic profile of XW003 Injection as a single dose in 6-10 subjects with normal renal function.; This cohort evaluated the pharmacokinetic profile of XW003 Injection administered as a single dose in 6-10 subjects with mild renal insufficiency.; This cohort evaluated the pharmacokinetic profile of XW003 Injection administered as a single dose in 6-10 subjects with moderate renal insufficiency. | Clinical Trial Center of Third Xiangya Hospital of Central South University; Third Xiangya Hospital, Central South University, Hangzhou Sciwind Biotechnology Co | diabetic nephropathy | | | | |
